Discussion| Volume 159, ISSUE 1, P170-171, January 2016


    Published:November 05, 2015DOI:
        Dr Steven K. Libutti (Bronx, NY): No disclosures. Very interesting work, and obviously anaplastic thyroid cancer represents a significant problem in our management of patients with thyroid cancer. Epithelial-to-mesenchymal transition is a critical pathway in the transition of cells to a more invasive phenotype. In alluding to some of the animal data that you've had or looked at with this target, how druggable is this target? In terms of thinking toward the future of designing therapies that you will be able to use to attack this, how successful are agents so far that can be used to attack it when converted to things you can give to mice and then hopefully humans in terms of dosing, pharmicokinetics, et cetera?
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'


        Subscribe to Surgery
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect